Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis
In the literature review, contemporary data on immune pathogenesis of psoriasis and the emergence of comorbid states against the background of systemic chronic inflammation among patients is discussed. On the example of the apremilast medical preparation, the information on a new class of therapeuti...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2018-01-01
|
| Series: | Vestnik Dermatologii i Venerologii |
| Subjects: | |
| Online Access: | https://www.vestnikdv.ru/jour/article/view/343 |
| _version_ | 1797713129069608960 |
|---|---|
| author | A. A. Bakulev |
| author_facet | A. A. Bakulev |
| author_sort | A. A. Bakulev |
| collection | DOAJ |
| description | In the literature review, contemporary data on immune pathogenesis of psoriasis and the emergence of comorbid states against the background of systemic chronic inflammation among patients is discussed. On the example of the apremilast medical preparation, the information on a new class of therapeutic agents for the treatment of psoriasis and psoriatic arthritis – “small molecules” is given, including their physicochemical properties and action mechanism, as well as on the key differences from immune-suppressive and genetically engineered biological preparations. Data on large-scale international randomised clinical trials of the efficacy and safety of the PDE4 inhibitor of apremilast among patients with moderate to severe psoriasis and psoriatic arthritis is presented. The published international clinical recommendations on the use of apremilast among patients with psoriasis and psoriatic arthritis, the criteria for evaluating the response to therapy, as well as the potential profile of patients for the use of apremilast in real clinical practice are discussed. |
| first_indexed | 2024-03-12T07:31:51Z |
| format | Article |
| id | doaj.art-1bab8cdb282c4087a95f5b3dbfafe6dd |
| institution | Directory Open Access Journal |
| issn | 0042-4609 2313-6294 |
| language | English |
| last_indexed | 2024-03-12T07:31:51Z |
| publishDate | 2018-01-01 |
| publisher | State Scientific Center of Dermatovenereology and Cosmetology |
| record_format | Article |
| series | Vestnik Dermatologii i Venerologii |
| spelling | doaj.art-1bab8cdb282c4087a95f5b3dbfafe6dd2023-09-02T21:44:59ZengState Scientific Center of Dermatovenereology and CosmetologyVestnik Dermatologii i Venerologii0042-46092313-62942018-01-0105899610.25208/0042-4609-2017-93-5-89-96338Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic ArthritisA. A. Bakulev0Saratov State Medical University named after V. I. Razumovsky of the Ministry of Health of Russian Federation, SaratovIn the literature review, contemporary data on immune pathogenesis of psoriasis and the emergence of comorbid states against the background of systemic chronic inflammation among patients is discussed. On the example of the apremilast medical preparation, the information on a new class of therapeutic agents for the treatment of psoriasis and psoriatic arthritis – “small molecules” is given, including their physicochemical properties and action mechanism, as well as on the key differences from immune-suppressive and genetically engineered biological preparations. Data on large-scale international randomised clinical trials of the efficacy and safety of the PDE4 inhibitor of apremilast among patients with moderate to severe psoriasis and psoriatic arthritis is presented. The published international clinical recommendations on the use of apremilast among patients with psoriasis and psoriatic arthritis, the criteria for evaluating the response to therapy, as well as the potential profile of patients for the use of apremilast in real clinical practice are discussed.https://www.vestnikdv.ru/jour/article/view/343psoriasispsoriatic arthritisimmune systempathogenesiscomorbid statestherapysmall moleculesaprimilastsoriasispsoriatic arthritisimmune systempathogenesiscomorbid statestherapysmall moleculesaprimilastefficiencyrecommendations for use |
| spellingShingle | A. A. Bakulev Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis Vestnik Dermatologii i Venerologii psoriasis psoriatic arthritis immune system pathogenesis comorbid states therapy small molecules aprimilast soriasis psoriatic arthritis immune system pathogenesis comorbid states therapy small molecules aprimilast efficiency recommendations for use |
| title | Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
| title_full | Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
| title_fullStr | Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
| title_full_unstemmed | Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
| title_short | Signaling Рathway Blockers: Action Mechanism, Efficacy, Safety of Therapy for Patients with Psoriasis and Psoriatic Arthritis |
| title_sort | signaling рathway blockers action mechanism efficacy safety of therapy for patients with psoriasis and psoriatic arthritis |
| topic | psoriasis psoriatic arthritis immune system pathogenesis comorbid states therapy small molecules aprimilast soriasis psoriatic arthritis immune system pathogenesis comorbid states therapy small molecules aprimilast efficiency recommendations for use |
| url | https://www.vestnikdv.ru/jour/article/view/343 |
| work_keys_str_mv | AT aabakulev signalingrathwayblockersactionmechanismefficacysafetyoftherapyforpatientswithpsoriasisandpsoriaticarthritis |